NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $21.54 -1.60 (-6.91%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$21.09▼$23.3550-Day Range$15.71▼$23.4952-Week Range$15.28▼$57.90Volume1.86 million shsAverage Volume1.65 million shsMarket Capitalization$2.60 billionP/E RatioN/ADividend YieldN/APrice Target$31.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get 10x Genomics alerts: Email Address 10x Genomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside46.7% Upside$31.60 Price TargetShort InterestHealthy8.65% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment0.54Based on 22 Articles This WeekInsider TradingSelling Shares$316,794 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.35) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.71 out of 5 starsMedical Sector51st out of 910 stocksAnalytical Instruments Industry3rd out of 26 stocks 4.3 Analyst's Opinion Consensus Rating10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst Coverage10x Genomics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.65% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in 10x Genomics has recently decreased by 6.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) Score10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.Environmental SustainabilityThe Environmental Impact score for 10x Genomics is -0.73. Previous Next 2.5 News and Social Media Coverage News Sentiment10x Genomics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for 10x Genomics this week, compared to 5 articles on an average week.Search Interest10 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $316,794.00 in company stock.Percentage Held by Insiders10.03% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.35) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -9.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -9.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about 10x Genomics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About 10x Genomics Stock (NASDAQ:TXG)10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More TXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXG Stock News HeadlinesAugust 27, 2024 | insidertrades.comInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CFO Sells 2,961 Shares of StockSeptember 7 at 1:15 AM | americanbankingnews.comEquities Analysts Set Expectations for 10x Genomics, Inc.'s Q3 2024 Earnings (NASDAQ:TXG)September 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.September 6 at 4:25 AM | americanbankingnews.com10x Genomics (NASDAQ:TXG) Stock Rating Reaffirmed by StephensSeptember 5 at 10:53 AM | markets.businessinsider.comBuy Rating Justified for 10x Genomics Amid Strategic Launch and Growth PotentialSeptember 5 at 2:43 AM | americanbankingnews.comLeerink Partners Initiates Coverage on 10x Genomics (NASDAQ:TXG)September 4 at 7:49 AM | americanbankingnews.com10x Genomics (NASDAQ:TXG) Upgraded to Strong-Buy at Leerink PartnrsSeptember 4 at 12:24 AM | markets.businessinsider.comBuy Rating Affirmed for 10x Genomics on Strong Spatial Business Growth and Market LeadershipSeptember 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.September 3, 2024 | benzinga.comIn-Depth Examination Of 11 Analyst Recommendations For 10x GenomicsSeptember 3, 2024 | msn.comLeerink Partners Initiates Coverage of 10x Genomics (TXG) with Outperform RecommendationSeptember 3, 2024 | prnewswire.com10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell ResearchAugust 31, 2024 | americanbankingnews.comAnalysts Set 10x Genomics, Inc. (NASDAQ:TXG) Target Price at $31.46August 29, 2024 | americanbankingnews.comInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $152,054.97 in StockAugust 29, 2024 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Insider Sells $98,028.03 in StockAugust 29, 2024 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $66,711.33 in StockAugust 23, 2024 | seekingalpha.comTXG 10x Genomics, Inc.August 22, 2024 | prnewswire.com10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceSee More Headlines Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TXG CUSIPN/A CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,259Year FoundedN/APrice Target and Rating Average Stock Price Target$31.60 High Stock Price Target$60.00 Low Stock Price Target$16.00 Potential Upside/Downside+46.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-255,100,000.00 Net Margins-37.90% Pretax Margin-36.92% Return on Equity-28.23% Return on Assets-21.95% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio4.42 Sales & Book Value Annual Sales$618.73 million Price / Sales4.19 Cash FlowN/A Price / Cash FlowN/A Book Value$6.01 per share Price / Book3.58Miscellaneous Outstanding Shares120,490,000Free Float107,215,000Market Cap$2.60 billion OptionableOptionable Beta1.85 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Serge Saxonov Ph.D. (Age 47)Co-Founder, CEO & Director Comp: $837.68kDr. Benjamin J. Hindson Ph.D. (Age 49)Co-Founder, President, Chief Scientific Officer & Director Comp: $615.96kMr. Justin J. McAnear (Age 48)Chief Financial Officer Comp: $535.91kMr. Eric S. Whitaker Esq. (Age 57)Chief Legal Officer Comp: $558.97kMr. Michael Schnall-LevinFounding Scientist & CTOMs. Cassie CorneauManager of Investor Relations and Strategic FinanceMs. Rebecca PortChief People OfficerMore ExecutivesKey CompetitorsBerkeley LightsNASDAQ:BLIBrukerNASDAQ:BRKRBio-Rad LaboratoriesNYSE:BIOBio-Rad LaboratoriesNYSE:BIO.BOlink Holding AB (publ)NASDAQ:OLKView All CompetitorsInsiders & InstitutionsSerge SaxonovSold 6,749 sharesTotal: $152,054.97 ($22.53/share)Benjamin J HindsonSold 4,351 sharesTotal: $98,028.03 ($22.53/share)Justin J McanearSold 2,961 sharesTotal: $66,711.33 ($22.53/share)Truist Financial CorpSold 804 shares on 8/21/2024Ownership: 0.009%Algert Global LLCBought 33,364 shares on 8/16/2024Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $55.96 at the beginning of the year. Since then, TXG stock has decreased by 61.5% and is now trading at $21.54. View the best growth stocks for 2024 here. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings data on Thursday, August, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.15. The company earned $153.10 million during the quarter, compared to analysts' expectations of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative trailing twelve-month return on equity of 28.23%. What is Serge Saxonov's approval rating as 10x Genomics' CEO? 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did 10x Genomics IPO? 10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? Top institutional shareholders of 10x Genomics include ARK Investment Management LLC (7.82%), Sumitomo Mitsui Trust Holdings Inc. (5.15%), Baillie Gifford & Co. (2.30%) and Deerfield Management Company L.P. Series C (0.50%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Mathai Mammen, Justin J Mcanear, James Wilbur, Sridhar Kosaraju and Bradford Crutchfield. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TXG) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TXG Stock Alerts